Registration Programme Overview Exhibition Virtual Exhibition Satellite Programme Hotel Information VISA Letter Application

 

Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Contact lens-assisted collagen cross-linking

Poster Details


First Author: E.Mahfoudi ALGERIA

Co Author(s): N. Benmerzouga-Mahfoudi   A. Snani   M. Djoual              

Abstract Details

Purpose:

To evaluate epi-off cross-linking assisted by contact lens; practiced on keratoconus with corneal thickness less than 420μm.

Setting:

Saint -Cloud Clinic/Al Farabi Clinic Annaba -Algeria

Methods:

A retrospective study from December 2015 to May 2017; in 34 patients (59 eyes) with progressive keratoconus with a corneal thickness between 370 and 420 μm, treated by epi-off crosslinking assisted by contact lens( Daily Disposable Soflens);We studied : per-operative Corneal thickness gain (pocket II-Quantel).and analyzed the values ​​pre-operative and 6 to 12 months post-operative : (correlation test, p <0.05, SPSS 23) of the Kmax (pentacamHR-Oculus), and the visual acuity.

Results:

The per-operative pachymetric gain (after pausing the lens) was 93 to 118 μm with an average of 108.43 ± 7.47 um. We noted :a preservation of UCVA in 52 eyes ( 0.12 +/ -0.05 to 6 and 12 months post-operative),and BCVA in 51 eyes ( 0.50 +/ -0.21 at 6 and 12 months post-operative),a stabilization of Kmax in 51 eyes ( Mean of 55.94 +/-2.73 vs 56.05 +/ - 2.80) to 6 and 12 months .

Conclusions:

The only treatment currently shown to be effective in stiffening the corneal stroma and thus slowing the progression of keratoconus is corneal collagen crosslinking (CXL). When the cornea is fine the CACXL would be an interesting alternative increasing the chances of effectiveness of treatment which is limited by the absence of de-epithelialization. In our practice; we favor epi-off cross-linking for any progressive keratoconus whatever the corneal thickness . A greater cohort and a longer follow-up (retreat) would allow the validation of this protocol.

Financial Disclosure:

None

Back to Poster listing